Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601378 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT02601378 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 107 participants.
The verdict
NCT02601378, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
Interventions
- DRUG LXS196
- DRUG LXS196 and HDM201
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2016-02-01 |
| Est. Completion | 2022-01-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601378
The ClinicalTrials.gov registry entry for NCT02601378 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LXS196 is the first listed.
NCT02601378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601378 about?
NCT02601378 is a clinical study titled "A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.". This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of LXS196 as a single agent and in combination with HDM201 in patients with metastatic uveal melanoma.
What is the current status of trial NCT02601378?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2016-02-01. Estimated completion is 2022-01-07.
What interventions are being tested in trial NCT02601378?
The interventions under investigation include: LXS196 (DRUG), LXS196 and HDM201 (DRUG).
Who is sponsoring clinical trial NCT02601378?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.